References
- Peris K, Fortina AB, Bianchi L, et al. Update on the management of pediatric psoriasis: an Italian consensus. Dermatol Ther. 2022;12(8):1–3.
- Gargiulo L, Ibba L, Pavia G, et al. Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series. J Dermatolog Treat. 2023;34(1):2183729.
- Megna M, Fornaro L, De Lucia M, et al. A case of pediatric psoriasis successfully and rapidly treated with ixekizumab. Dermatol Ther. 2021;34(6):e15108.
- Sun HY, Phan K, Paller AS, et al. Biologics for pediatric psoriasis: a systematic review and meta-analysis. Pediatr Dermatol. 2022;39(1):42–48.
- Paller AS, Seyger MMB, Alejandro Magariños G, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS). Br J Dermatol. 2020;183(2):231–241.
- Paller AS, Seyger MMB, Magariños GA, et al. Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial. JAMA Dermatol. 2022;158(5):533–541.
- Gargiulo L, Pavia G, Valenti M, et al. Safety of biologic therapies in patients with moderate-to-severe plaque psoriasis and concomitant viral hepatitis: a monocentric retrospective study. Dermatol Ther. 2022;12(5):1263–1270.